In the Journals

The Bolger Conference on PDE-5 Inhibition and HIV Risk: Implications for Health Policy and Prevention.

January 2, 2007

Authors: Rosen RC, Catania JA, Ehrhardt AA, Burnett AL, Lue TF, McKenna K, et al. 

Journal: Sex Med 2006; 3:960-975.

Editorial:  Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission.  An evaluation of the scientific research, clinical and ethical considerations, and public policy implications of this topic was performed by a National Institute of Mental Health-funded, multidisciplinary conference of experts.  It was acknowledged that PDE-5 inhibitor use is co-associated with recreational or “party” drug use, consistent with a growing understanding that there are emerging patterns of sexual behavior associated with the availability and use of this therapy.  It is purposeful to increase education among professionals and the public regarding potential risks associated with recreational use of PDE-5 inhibitors and promote initiatives for the prevention of high-risk sexual behavior.

Arthur L. Burnett, M.D.